INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 12, 2021 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Bona fide gift | 82,108 | -- | 82,108 |
| Dec 31, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Other acquisition or disposition | -- | -- | 5,821 |
| Dec 31, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Other acquisition or disposition | -- | -- | 376,861 |
| Dec 31, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 620,270 | -- | 620,270 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | $52.03 | 880,938 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 130,714 | $483.25 | 750,224 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | $52.03 | 908,303 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 86,096 | $483.25 | 822,207 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | -- | 158,079 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.